Europe — EMA
Novothirteen (Catridecacog)
Catridecacog, the active ingredient in Novothirteen, is a hemostatic agent presented as a sterile powder for intravenous use. It is used to control bleeding in patients with congenital factor XIII deficiency.
Request sourcing
What is Catridecacog?
Catridecacog, the active ingredient in Novothirteen, is a hemostatic agent presented as a sterile powder for intravenous use. It is used to control bleeding in patients with congenital factor XIII deficiency. GNH USA supplies Novothirteen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.
GNH USA supplies Novothirteen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.
What is Catridecacog used for?
Novothirteen is a recombinant factor XIII A subunit used to replace deficient clotting activity in the intrinsic pathway of blood coagulation.
- Congenital factor XIII deficiency: Provides long‑lasting hemostatic protection for prophylactic or acute bleeding episodes. - Peri‑operative surgical procedures: Reduces risk of intra‑operative bleeding in patients with known factor XIII deficiency. - Trauma‑related bleeding in patients with factor strength XIII deficiency : S t
What are the side effects of Catridecacog?
It ...
